Do novel oral anticoagulants (NOACs) reduce the composite of stroke, TIA, major bleed, or death compared to warfarin in adults with transthyretin cardiac amyloidosis and atrial fibrillation?
In patients with transthyretin cardiac amyloidosis and atrial fibrillation, NOACs and warfarin showed no significant difference in the combined risk of stroke, TIA, major bleeding, or death.
Background Atrial fibrillation (AF) is common in patients with transthyretin cardiac amyloidosis (ATTR-CA). The optimal strategy to prevent strokes in patients with ATTR-CA and AF is unknown.Objectives To compare outcomes in patients with ATTR-CA and AF treated with warfarin versus novel oral anticoagulants (NOACs).Methods This study was a retrospective analysis of patients with ATTR-CA stratified by presence or absence of AF and anticoagulation therapy. The primary outcome included a time to event analysis for the combined outcomes of stroke, transient ischaemic attack (TIA), major bleed, or death.Results Of 290 patients, 217 patients (74.8%) had AF. Of those with AF (n = 217), 78 (35.9%) patients received warfarin compared with 116 (53.5%) patients who received NOACs. There were 17 thrombotic events, all in those diagnosed with AF compared with none in the patients without AF (p = .01). Over a mean follow-up of 2.4 years (range 0.1–12) there was no difference in primary outcome between those with AF treated with warfarin compared with NOACs (p = .35).Conclusion Patient with ATTR-CA and AF are at increased risk for stroke compared to patients with ATTR-CA and without AF. Thrombotic events and major bleeds did not differ between those who received warfarin and NOACs.
Mitrani et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: